View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 11, 2017

Hope for sufferers with extremely rare form of liver cancer

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare form of liver cancer that affects young adults with no history of primary liver disease or cirrhosis.

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare form of liver cancer that affects young adults with no history of primary liver disease or cirrhosis. 

Because the condition affects only one in 5,000,000 people, it has suffered from a lack of research effort in the past.

This means that little is known of FL-HCC molecular pathogenesis and, as it does not respond well to chemotherapy, surgery is the only option for sufferers.

However, a unique target identified in this condition could lead to the possibility of a targeted treatment.

A promising target

A recent study identified a genetic alteration found in livers affected by FL-HCC, but not in healthy livers.

Evidence suggests that the alteration, called the DNAJB1-PRKACA chimeric transcript, is present in all FL-HCC cases, implying that it contributes to tumor formation and growth.

If this is the case, a drug therapy that acts against this target could meet a significant unmet need in this indication.

Blueprint Medicines Corp currently has a small molecule drug that acts against this target in the discovery stage of development.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena